[Primary hemostasis in mixed connective tissue disease].

Area of Science:

• Rheumatology
• Hematology
• Vascular Biology

Context:

• Mixed connective tissue disease (MCTD) is an autoimmune disorder with overlapping features of systemic lupus erythematosus, scleroderma, and polymyositis.
• Vascular complications, including thrombosis and pulmonary hypertension, are significant causes of morbidity and mortality in MCTD patients.
• Endothelial dysfunction and platelet activation are implicated in the pathogenesis of various autoimmune and connective tissue diseases.

Purpose:

• To investigate the levels and activity of Willebrand factor (vWF) in patients with mixed connective tissue disease.
• To assess platelet activation markers and their correlation with clinical manifestations and autoantibodies in MCTD.
• To explore the role of endothelial and platelet dysfunction in the development of vascular complications in MCTD.

Summary:

• Willebrand-factor antigen levels and activity were elevated in 22 patients with mixed connective tissue disease.
• High vWF levels correlated with thrombocytopenia, prior thrombotic events, pulmonary vascular lesions, and the presence of antiendothelial antibodies.
• Increased platelet activation was observed, particularly in patients with antibodies and thrombocytopenia, suggesting a role in vascular pathology.

Impact:

• These findings suggest that altered endothelial and platelet function are key contributors to vascular complications in mixed connective tissue disease.
• Identifying these hemostatic abnormalities may lead to improved diagnostic strategies and targeted therapies for MCTD-associated vascular disease.
• This research underscores the importance of evaluating hemostatic parameters in the management of patients with mixed connective tissue disease.